Gilead Sciences (GILD) Soars 3.73% on Strong Q2 Earnings

Gilead Sciences' stock surged 3.73% in pre-market trading on August 8, 2025, driven by a series of positive developments and strong financial performance.

Gilead Sciences has raised its full-year outlook after exceeding expectations, with a significant boost in revenue and earnings. The company's second-quarter revenue increased by 2% to $7.1 billion, primarily driven by higher sales in HIV treatments, Livdelzi® (seladelpar), and Trodelvy®. This performance has led to a revised full-year forecast, with adjusted earnings per share expected to range from $7.95 to $8.25, up from the previous estimate of $7.70 to $8.10.

The company's earnings for the second quarter of 2025 came in at $1.960 billion, or $1.56 per share, marking a substantial increase from the previous year's $1.614 billion, or $1.29 per share. This strong financial performance has been attributed to the rising demand for HIV treatments and the successful launch of new drugs.

Gilead Sciences' valuation remains attractive, with the stock trading below peer multiples and offering robust margins. The company also boasts a sector-leading dividend yield above 2.8%, making it an appealing investment option for those seeking both growth and income.